Heart Tronics Competitors

Medtronic (NYSE:MDT) and Heart Tronics (OTCMKTS:HRTT) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, institutional ownership, earnings and risk.

Institutional & Insider Ownership

79.2% of Medtronic shares are owned by institutional investors. 0.5% of Medtronic shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Medtronic and Heart Tronics' revenue, earnings per share (EPS) and valuation.

Medtronic has higher revenue and earnings than Heart Tronics.

Risk and Volatility

Medtronic has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500. Comparatively, Heart Tronics has a beta of 1024.78, suggesting that its share price is 102,378% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations for Medtronic and Heart Tronics, as reported by MarketBeat.com.

Medtronic presently has a consensus target price of $125.3333, suggesting a potential downside of 2.32%. Given Medtronic's higher possible upside, analysts plainly believe Medtronic is more favorable than Heart Tronics.

Profitability

This table compares Medtronic and Heart Tronics' net margins, return on equity and return on assets.

Summary

Medtronic beats Heart Tronics on 9 of the 10 factors compared between the two stocks.

Heart Tronics (OTCMKTS:HRTT) and Sonova (OTCMKTS:SONVY) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, risk and profitability.

Profitability

This table compares Heart Tronics and Sonova's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Heart Tronics and Sonova, as reported by MarketBeat.com.

Volatility & Risk

Heart Tronics has a beta of 1024.78, indicating that its stock price is 102,378% more volatile than the S&P 500. Comparatively, Sonova has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500.

Earnings & Valuation

This table compares Heart Tronics and Sonova's top-line revenue, earnings per share and valuation.

Sonova has higher revenue and earnings than Heart Tronics.

Institutional and Insider Ownership

1.1% of Sonova shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Sonova beats Heart Tronics on 3 of the 4 factors compared between the two stocks.

Varian Medical Systems (NYSE:VAR) and Heart Tronics (OTCMKTS:HRTT) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, profitability and valuation.

Profitability

This table compares Varian Medical Systems and Heart Tronics' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Varian Medical Systems and Heart Tronics' gross revenue, earnings per share and valuation.

Varian Medical Systems has higher revenue and earnings than Heart Tronics.

Institutional & Insider Ownership

87.0% of Varian Medical Systems shares are held by institutional investors. 0.8% of Varian Medical Systems shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and price targets for Varian Medical Systems and Heart Tronics, as reported by MarketBeat.

Varian Medical Systems presently has a consensus price target of $170.9167, indicating a potential downside of 3.48%. Given Varian Medical Systems' higher possible upside, equities analysts plainly believe Varian Medical Systems is more favorable than Heart Tronics.

Risk and Volatility

Varian Medical Systems has a beta of 1.06, meaning that its share price is 6% more volatile than the S&P 500. Comparatively, Heart Tronics has a beta of 1024.78, meaning that its share price is 102,378% more volatile than the S&P 500.

Summary

Varian Medical Systems beats Heart Tronics on 7 of the 8 factors compared between the two stocks.

Heart Tronics (OTCMKTS:HRTT) and Masimo (NASDAQ:MASI) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations and earnings.

Volatility & Risk

Heart Tronics has a beta of 1024.78, suggesting that its stock price is 102,378% more volatile than the S&P 500. Comparatively, Masimo has a beta of 0.87, suggesting that its stock price is 13% less volatile than the S&P 500.

Valuation & Earnings

This table compares Heart Tronics and Masimo's revenue, earnings per share and valuation.

Masimo has higher revenue and earnings than Heart Tronics.

Profitability

This table compares Heart Tronics and Masimo's net margins, return on equity and return on assets.

Institutional and Insider Ownership

81.6% of Masimo shares are held by institutional investors. 11.5% of Masimo shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings for Heart Tronics and Masimo, as provided by MarketBeat.

Masimo has a consensus target price of $272.20, indicating a potential upside of 11.84%. Given Masimo's higher probable upside, analysts clearly believe Masimo is more favorable than Heart Tronics.

Summary

Masimo beats Heart Tronics on 8 of the 9 factors compared between the two stocks.

Getinge (OTCMKTS:GNGBY) and Heart Tronics (OTCMKTS:HRTT) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings and institutional ownership.

Institutional and Insider Ownership

0.0% of Getinge shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Getinge and Heart Tronics' gross revenue, earnings per share (EPS) and valuation.

Getinge has higher revenue and earnings than Heart Tronics.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Getinge and Heart Tronics, as reported by MarketBeat.

Risk & Volatility

Getinge has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500. Comparatively, Heart Tronics has a beta of 1024.78, suggesting that its share price is 102,378% more volatile than the S&P 500.

Profitability

This table compares Getinge and Heart Tronics' net margins, return on equity and return on assets.

Summary

Getinge beats Heart Tronics on 6 of the 7 factors compared between the two stocks.

Heart Tronics (OTCMKTS:HRTT) and LivaNova (NASDAQ:LIVN) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, analyst recommendations, dividends, earnings and institutional ownership.

Profitability

This table compares Heart Tronics and LivaNova's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Heart Tronics and LivaNova's top-line revenue, earnings per share and valuation.

Heart Tronics has higher earnings, but lower revenue than LivaNova.

Insider and Institutional Ownership

89.1% of LivaNova shares are owned by institutional investors. 0.5% of LivaNova shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Volatility and Risk

Heart Tronics has a beta of 1024.78, indicating that its stock price is 102,378% more volatile than the S&P 500. Comparatively, LivaNova has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Heart Tronics and LivaNova, as provided by MarketBeat.com.

LivaNova has a consensus target price of $69.3333, indicating a potential downside of 14.72%. Given LivaNova's higher possible upside, analysts clearly believe LivaNova is more favorable than Heart Tronics.

Summary

LivaNova beats Heart Tronics on 7 of the 9 factors compared between the two stocks.